Table 3.
Treatment-emergent adverse events reported during the study.
| Oxybutynin 100 mg (n = 8) |
||
|---|---|---|
| Event n | Subject n (%) | |
| All events | 11 | 5 (62.5) |
| Eye disorders | ||
| Blurry vision | 1 | 1 (12.5) |
| Gastrointestinal disorders | ||
| Dry mouth | 1 | 1 (12.5) |
| Lip dry | 1 | 1 (12.5) |
| Nausea | 1 | 1 (12.5) |
| General and administration conditions | ||
| Fatigue | 2 | 2 (25.0) |
| Feeling hot | 1 | 1 (12.5) |
| Nervous system disorders (headache) | 4 | 3 (37.5) |